Citations

Clear

1422 citation(s) found for "White, JB".

History and Justification of a National Blood Pressure Measurement Validated Device Listing
Cohen, Jordana B. , Padwal, Raj , Gutkin, Michael , Bloch, Michael J. , Germino, F. Wilford, Sica, Domenic A., Viera, Anthony J. , Bluml, Benjamin M. , White, William B. , Taler, Sandra J. , Yarows, Steven A. , Green, Beverly B. , Shimbo, Daichi , Townsend, Raymond R.

Mayo Clinic

Hypertension | December 24, 2018 | Volume: 73 | Issue: 2 | Pages: 258-264

10.1161/hypertensionaha.118.11990 | PMID 30580681 Get It

Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk
Yang, Yaohua , Wu, Lang , Shu, Xiao-Ou , Lu, Yingchang , Beeghly‐Fadiel, Alicia, Li, Bingshan , Ye, Fei , Banerjee, Susana , Benı́tez, Javier , Chang‐Claude, Jenny , Chen, Kexin , DeFazio, Anna , Dörk, Thilo , Eccles, Diana M., Edwards, Digna Velez, Fasching, Peter A. , Fortner, Renée T. , Gayther, Simon A. , Goode, Ellen L. , Goodman, Marc T. , Heitz, Florian , Hildebrandt, Michelle A.T., Høgdall, Estrid , Høgdall, Claus , Huntsman, David G. , Kar, Siddhartha , Kelemen, Linda E. , Koushik, Anita , Lambrechts, Diether , Le, Nhu D. , Levine, Douglas A. , Massuger, Leon F.A.G. , Matsuo, Keitaro , May, Taymaa, McNeish, Iain A. , Menon, Usha , Monteiro, Álvaro N.A. , Moorman, Patricia G. , Moysich, Kirsten B. , Ness, Roberta B., Olsson, Håkan , Onland‐Moret, N. Charlotte , Park, Sue K. , Paul, James , Pearce, Celeste Leigh, Phelan, Catherine M., Pike, Malcolm C. , Ramus, Susan J. , Ríboli, Elio , Rodríguez‐Antona, Cristina , Romieu, Isabelle, Sandler, Dale P. , Schildkraut, Joellen M. , Shan, Kang, Sieh, Weiva , Stampfer, Meir J. , Sutphen, Rebecca , Swerdlow, Anthony J. , Szafron, Lukasz M. , Teo, Soo‐Hwang , Tworoger, Shelley S. , Webb, Penelope M. , Wentzensen, Nicolas , Woo, Yin Ling , Wu, Anna H. , Chenevix‐Trench, Georgia , Sellers, Thomas A. , Long, Jirong , Eccles, Diana , Lambrechts, Diether , Chen, Kexin , Shu, Xiao-Ou , Brenton, James D , Chang-Claude, Jenny , Fazio, Anna de , Dennis, Joe , Fasching, Peter A , Fortner, Renée T , Giles, Graham G , Harris, Holly R , Kiemeney, Lambertus A , Kjaer, Susanne K , Koushik, Anita , McNeish, Iain A , Menon, Usha , Monteiro, Alvaro N , Nevanlinna, H , Park, Sue K , Paul, James , Ramus, Susan J , Rodríguez-Antona, Cristina , Sandler, Dale P , Szafron, Lukasz M , Teo, Soo H , Tworoger, Shelley S , Webb, Penelope M , Wolk, Alicja , Dörk, Thilo , Lambrechts, Diether , Eccles, Diana , Swerdlow, Anthony J , Moysich, Kirsten , Matsuo, Keitaro , Heitz, Florian , Lambrechts, Diether , Sieh, Weiva , Benitez, Javier , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Kar, Siddhartha , Riboli, Elio , Goodman, Marc T , Cai, Qiuyin , Beeghly‐Fadiel, Alicia , Berchuck, Andrew , Anton‐Culver, Hoda , Bjørge, Line , Brenton, James D. , Bützow, Ralf C. , Campbell, Ian , Cook, Linda S. , Cramer, Daniel W. , Doherty, Jennifer A. , Edwards, Digna R. Velez , Giles, Graham G. , Glasspool, Rosalind , Gronwald, Jacek , Harris, Holly R. , Hildebrandt, Michelle A.T. , Karlan, Beth Y. , Kiemeney, Lambertus A. , Kjær, Susanne K. , Modugno, Francesmary , Nevanlinna, Heli , Pejovic, Tanja B. , Setiawan, Veronica Wendy , Shan, Kang, Siddiqui, Nadeem , Tyrer, Jonathan P. , White, Emily , Willett, Walter C. , Wolk, Alicja , Li, Yan , Yannoukakos, Drakoulis , Pharoah, Paul D.P. , Zheng, Wei , Yang, Yaohua , Chen, Kexin

Mayo Clinic

Cancer Research | December 17, 2018 | Volume: 79 | Issue: 3 | Pages: 505-517

10.1158/0008-5472.can-18-2726 | PMID 30559148 Get It

Abstract DNA methylation is instrumental for gene regulation. Global changes in the epigenetic landscape have been recognized as a hallmark of cancer. However, the role of DNA methylation in epithelial ovarian cancer (EOC) remains unclear. In this study, high-density genetic and DNA methylation data in white blood cells from the Framingham Heart Study (N = 1,595) were used to build genetic models to predict DNA methylation levels. These prediction models were then applied to the summary statistics of a genome-wide association study (GWAS) of ovarian cancer including 22,406 EOC cases and 40,941 controls to investigate genetically predicted DNA methylation levels in association with EOC risk. Among 62,938 CpG sites investigated, genetically predicted methylation levels at 89 CpG were significantly associated with EOC risk at a Bonferroni-corrected threshold of P < 7.94 × 10−7. Of them, 87 were located at GWAS-identified EOC susceptibility regions and two resided in a genomic region not previously reported to be associated with EOC risk. Integrative analyses of genetic, methylation, and gene expression data identified consistent directions of associations across 12 CpG, five genes, and EOC risk, suggesting that methylation at these 12 CpG may influence EOC risk by regulating expression of these five genes, namely MAPT, HOXB3, ABHD8, ARHGAP27, and SKAP1. We identified novel DNA methylation markers associated with EOC risk and propose that methylation at multiple CpG may affect EOC risk via regulation of gene expression. Significance: Identification of novel DNA methylation markers associated with EOC risk suggests that methylation at multiple CpG may affect EOC risk through regulation of gene expression.
Transcriptome and epigenome landscape of human cortical development modeled in organoids
Amiri, Anahita , Coppola, Gianfilippo , Scuderi, Soraya , Wu, Feinan , Roychowdhury, Tanmoy , Liu, Fuchen , Pochareddy, Sirisha , Shin, Yurae , Safi, Alexias , Song, Lingyun , Sousa, André M. M. , Crawford, Gregory E. , Šestan, Nenad , Abyzov, Alexej , Vaccarino, Flora M. , An, Joon‐Yong , Armoskus, Christoper, Beach, Thomas G., Belmont, Judson, Bendl, Jaroslav , Borrman, Tyler , Brown, Leanne, Brown, Miguel , Brown, Mimi, Brunetti, Tonya M. , Burke, Emily E., Chae, Yooree, Charney, Alexander W. , Cherskov, Adriana , Choi, Jinmyung , Clarke, Declan , Valle, Diane M. Del , Devillers, Olivia, Dracheva, Stella , Emani, Prashant S. , Evgrafov, Oleg V. , Fitzgerald, Dominic , Flatow, Elie, Francoeur, Nancy , Fullard, John F. , Gao, Tianliuyun , Geschwind, Daniel H. , Giase, Gina , Goodman, Thomas, Grennan, Kay, Gu, Mengting , Hadjimichael, Evi , Hahn, Chang-Gyu, Haroutunian, Vahram , Huey, Jack , Ivanov, Nikolay A. , Jacobov, Rivka, Jiang, Yan , Jiang, Yi , Kassim, Bibi, Kefi, Amira , Kleiman, Joel E., Knowles, James A. , Kozlenkov, Alexey , Li, Zhen , Lipska, Barbara K., Mangravite, Lara M. , Mariani, Jessica , Mattei, Eugenio , Miller, Daniel J. , Moore, J. Russell, Peters, Mette A. , Pinto, Dalila , Polioudakis, Damon, Ray, Mohana, Reddy, Timothy E. , Rhie, Suhn K. , Santpere, Gabriel , Sheppard, Brooke , Shi, Xu , Shieh, Annie W. , Shin, Joo Heon , Spitsyna, Valeria N. , Szatkiewicz, Jin , Szekely, Anna , Wang, Yongjun , Weissman, Sherman M., Weng, Zhiping , White, Kevin P. , Willsey, Jeremy A., Witt, Heather , Won, Hyejung , Xia, Yan , Xu, Min , Yang, Mo , Zandi, Peter P. , Zhang, Jing , Zharovsky, Elizabeth , Sousa, André M M , Gerstein, Mark , Crawford, Gregory E , Sestan, Nenad , Abyzov, Alexej , Vaccarino, Flora M , Del Valle, Diane M , Zhu, Ying , Gerstein, Mark , Akbarian, Schahram , Ashley‐Koch, Allison E. , Bryois, Julien , Camarena, Adrian , Carlyle, Becky Catherine , Chen, Chao , Cheng, Lijun , Collado‐Torres, Leonardo , Dai, Rujia , Torre-Ubieta, Luis de la , Farnham, Peggy , Gandal, Michael J. , Garrett, Melanie E , Girdhar, Kiran Kumar , Giusti‐Rodríguez, Paola , Goes, Fernando , Goodman, Thomas, Gürsoy, Gamze , Hauberg, Mads E. , Hoffman, Gabriel E. , Hyde, Thomas M , Jaffe, Andrew E. , Johnson, Graham D. , Kim, Yunjung , Kitchen, Robert , Li, Mingfeng , Liu, Chunyu , Liu, Shuang , Moore, Jill, Nairn, Angus C. , Navarro, Fábio C. P. , Park, Royce , Pratt, Henry , Price, Amanda J. , Purcaro, Michael J. , Roussos, Panos , Sanders, Stephan , Schreiner, Shannon , Škarica, Mario , State, Matthew W. , Sullivan, Patrick F. , Swarup, Vivek , Tao, Ran , Bakel, Harm van , Wang, Daifeng , Warrell, Jonathan , Webster, Maree J. , Werling, Donna M. , Wiseman, Jennifer R. , Wray, Gregory A. , Yang, Yucheng

Mayo Clinic

Science | December 13, 2018 | Volume: 362 | Issue: 6420 | Pages: No page available

10.1126/science.aat6720 | PMID 30545853 Get It

INTRODUCTION The human cerebral cortex has undergone an extraordinary increase in size and complexity during mammalian evolution. Cortical cell lineages are specified in the embryo, and genetic and epidemiological evidence implicates early cortical development in the etiology of neuropsychiatric disorders such as autism spectrum disorder (ASD), intellectual disabilities, and schizophrenia. Most of the disease-implicated genomic variants are located outside of genes, and the interpretation of noncoding mutations is lagging behind owing to limited annotation of functional elements in the noncoding genome. RATIONALE We set out to discover gene-regulatory elements and chart their dynamic activity during prenatal human cortical development, focusing on enhancers, which carry most of the weight upon regulation of gene expression. We longitudinally modeled human brain development using human induced pluripotent stem cell (hiPSC)–derived cortical organoids and compared organoids to isogenic fetal brain tissue. RESULTS Fetal fibroblast–derived hiPSC lines were used to generate cortically patterned organoids and to compare oganoids’ epigenome and transcriptome to that of isogenic fetal brains and external datasets. Organoids model cortical development between 5 and 16 postconception weeks, thus enabling us to study transitions from cortical stem cells to progenitors to early neurons. The greatest changes occur at the transition from stem cells to progenitors. The regulatory landscape encompasses a total set of 96,375 enhancers linked to target genes, with 49,640 enhancers being active in organoids but not in mid-fetal brain, suggesting major roles in cortical neuron specification. Enhancers that gained activity in the human lineage are active in the earliest stages of organoid development, when they target genes that regulate the growth of radial glial cells. Parallel weighted gene coexpression network analysis (WGCNA) of transcriptome and enhancer activities defined a number of modules of coexpressed genes and coactive enhancers, following just six and four global temporal patterns that we refer to as supermodules, likely reflecting fundamental programs in embryonic and fetal brain. Correlations between gene expression and enhancer activity allowed stratifying enhancers into two categories: activating regulators (A-regs) and repressive regulators (R-regs). Several enhancer modules converged with gene modules, suggesting that coexpressed genes are regulated by enhancers with correlated patterns of activity. Furthermore, enhancers active in organoids and fetal brains were enriched for ASD de novo variants that disrupt binding sites of homeodomain, Hes1, NR4A2, Sox3, and NFIX transcription factors. CONCLUSION We validated hiPSC-derived cortical organoids as a suitable model system for studying gene regulation in human embryonic brain development, evolution, and disease. Our results suggest that organoids may reveal how noncoding mutations contribute to ASD etiology. Summary of the study, analyses, and main results. Data were generated for iPSC-derived human telencephalic organoids and isogenic fetal cortex. Organoids modeled embryonic and early fetal cortex and show a larger repertoire of enhancers. Enhancers could be divided into activators and repressors of gene expression. We derived networks of modules and supermodules with correlated gene and enhancer activities, some of which were implicated in autism spectrum disorders (ASD).
AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health
Lippman, Scott M. , Abate‐Shen, Cory , Maresso, Karen L. Colbert, Colditz, Graham A. , Dannenberg, Andrew J. , Davidson, Nancy E. , Szabó, Éva , Giuliano, Anna R. , Hait, William N., Lee, J. Jack, Kensler, Thomas W. , Kramer, Barnett S., Schmitz, Kathryn H. , Hawk, Ernest T. , Lee, J. Jack , Limburg, Paul, Colditz, Graham A , Schmitz, Kathryn H , Szabo, Eva , Lee, J Jack , Maresso, Karen Colbert , Disis, Mary Lenora , DuBois, Raymond N. , Lee, J. Jack, Limburg, Paul J. , Maitra, Anirban , Martı́nez, Marı́a Elena , Rebbeck, Timothy R. , Vilar, Eduardo , Abate-Shen, Cory

Mayo Clinic

Cancer Prevention Research | December 10, 2018 | Volume: 11 | Issue: 12 | Pages: 735-778

10.1158/1940-6207.capr-18-0421 | PMID 30530635 Get It

Abstract The recent pace, extent, and impact of paradigm-changing cancer prevention science has been remarkable. The American Association for Cancer Research (AACR) convened a 3-day summit, aligned with five research priorities: (i) Precancer Atlas (PCA). (ii) Cancer interception. (iii) Obesity-cancer linkage, a global epidemic of chronic low-grade inflammation. (iv) Implementation science. (v) Cancer disparities. Aligned with these priorities, AACR co-led the Lancet Commission to formally endorse and accelerate the NCI Cancer Moonshot program, facilitating new global collaborative efforts in cancer control. The expanding scope of creative impact is perhaps most startling—from NCI-funded built environments to AACR Team Science Awarded studies of Asian cancer genomes informing global primary prevention policies; cell-free epigenetic marks identifying incipient neoplastic site; practice-changing genomic subclasses in myeloproliferative neoplasia (including germline variant tightly linked to JAK2 V617F haplotype); universal germline genetic testing for pancreatic cancer; and repurposing drugs targeting immune- and stem-cell signals (e.g., IL-1β, PD-1, RANK-L) to cancer interception. Microbiota-driven IL-17 can induce stemness and transformation in pancreatic precursors (identifying another repurposing opportunity). Notable progress also includes hosting an obesity special conference (connecting epidemiologic and molecular perspectives to inform cancer research and prevention strategies), co-leading concerted national implementation efforts in HPV vaccination, and charting the future elimination of cancer disparities by integrating new science tools, discoveries and perspectives into community-engaged research, including targeted counter attacks on e-cigarette ad exploitation of children, Hispanics and Blacks. Following this summit, two unprecedented funding initiatives were catalyzed to drive cancer prevention research: the NCI Cancer Moonshot (e.g., PCA and disparities); and the AACR-Stand Up To Cancer bold “Cancer Interception” initiative.
The cost implications of palliative radiation therapy dose and fractionation for painful metastatic bone lesions.
Waddle, Mark R. , Kaleem, Tasneem , Stross, William C. , Malouff, Timothy D. , Jenkins, Mikayla, Pacitti, Delaney, DeVries, Matthew , Patibandla, Aditya, May, Jackson, White, Launia J. , Spaulding, Aaron , Naessens, James M. , Keole, Sameer R., Spaulding, Aaron , Daniel, J. , Miller, Robert C.

Mayo Clinic

Journal of Clinical Oncology | November 28, 2018 | Volume: 36 | Issue: 34_suppl | Pages: 145-145

10.1200/jco.2018.36.34_suppl.145 Get It

145 Background: Palliative radiation treatment (pRT) is used for symptomatic bone metastases (mets). Several fractionation schedules show equal efficacy for pain relief, and ASTRO’s Choosing Wisely recommends 8Gy x1, 4Gy x5, or 3Gy x10. This study aims to investigate the cost implications of pRT for bone mets. Methods: Patients (Pts) treated with pRT for bone mets at Mayo Clinic from 2007 - 2016 were included in this study. Costs for all services were subdivided into RT and total costs at 30 & 90 days (30D & 90D). Standardized costs were obtained from the Mayo Clinic Cost Data Warehouse and Medicare reimbursements were assigned to all services with cost to charge adjustments and 2017 GDP Implicit Price Deflator for inflation. Cost means were compared via the Kruskal-Wallis test. Results: 538 pts were treated with pRT, 124 receiving 8Gy x1, 204 receiving 4Gy x5, and 210 receiving 3Gy x10. Pts with breast and prostate cancer were most likely to be treated with 3Gy x10 and pts with GI and lung cancer were most likely to be treated with 8Gy x1. RT costs at 30D were $1,497, $1,891, and $1,982 (p=0.03) and RT costs at 90D were $2,602, $2,753, and $3,032 (p=0.08) for initial RT regimens of 8Gy x1, 4Gy x5, and 3Gy x10. Total costs of care at 30D were similar from $15,969 - 17,687 (p=0.6) and total costs at 90D were similar from $22,361 - 23,219 (p=0.7) between arms. A total of 23%, 28%, and 39% of pts were alive 2 years following pRT from each arm (p=0.07). Conclusions: This is the first study of its kind to analyze actual treatment costs for the three most common pRT regimens in bone mets. Single fraction RT was most used for pts with poor prognoses and was associated with lower RT costs at 30D, but similar RT costs at 90D, possibly due to retreatment. RT choice had no impact on overall costs of care at 30D or 90D. pRT remains of high value, representing only 11-13% of total costs.[Table: see text]
Toxicity following palliative radiation therapy for painful metastatic bone lesions.
Jenkins, Mikayla, Waddle, Mark R. , Kaleem, Tasneem , Stross, William C. , Malouff, Timothy D. , DeVries, Matthew , Pacitti, Delaney, May, Jackson, Patibandla, Aditya, White, Launia J. , Spaulding, Aaron , Naessens, James M. , Spaulding, Aaron , Miller, Robert C.

Mayo Clinic

Journal of Clinical Oncology | November 28, 2018 | Volume: 36 | Issue: 34_suppl | Pages: 126-126

10.1200/jco.2018.36.34_suppl.126 Get It

126 Background: Palliative radiation treatment (pRT) is a common and effective treatment for patients with symptomatic bone metastases. However, patients receiving RT for bone metastases often may have a poor performance status and are more likely to experience toxicity during or after treatment. This study aims to investigate the number and type of toxicity event occurring during or after pRT for bone metastases. Methods: Patients treated with RT for bone metastases at Mayo Clinic from 2007 to 2016 were included in this study. Demographic, disease, treatment, and toxicity information were collected. Specifically, toxicity events were identified as emergency department (ED) visits and inpatient hospitalization (IH) within 90 days, breaks in treatment >4 days, and excessive 30 day financial toxicity defined as standardized Medicare costs >1 standard deviation above the mean. RT treatment was compared by dose and fractionation via descriptive statistics. Results: A total of 538 patients treated with pRT were identified, 124 receiving 8Gy x1, 204 receiving 4Gy x5, and 210 receiving 3Gy x10. Patients with breast and prostate cancer were most likely to be treated with 3Gy x10 and patients with GI and Lung cancer were most likely to be treated with 8Gy x1. A description of the patient characteristics and toxicities are shown in Table 1. For 8Gy x1, 4Gy x5, and 3Gy x10 breaks in treatment were rare (0%, 2%, and 3.3%), ED visits (15%, 24%, & 28%), IH (12%, 23%, & 19%), and financial toxicity (13%, 18%, & 21%) were common. A total of 22.6%, 27.5%, and 38.6% of patients were alive two years following pRT from each group. Conclusions: Toxicity during or shortly after pRT of bone metastases is common. This study confirms that additional steps should be taken to monitor and mitigate toxicity in this vulnerable patient group. [Table: see text]
NIMG-16. IMPACT OF SEX DIFFERENCES AND TUMOR LOCATION ON SURVIVAL OUTCOMES IN GLIOBLASTOMA PATIENTS
Lorence, Julia, Johnston, Sandra K. , Ranjbar, Sara , Whitmire, Paula , Rickertsen, Cassandra , León, Gustavo De , Anderies, Barrett J. , White, Haylye, Singleton, Kyle , Hu, Leland , Mitchell, J. Ross , Porter, Alyx B. , Mrugała, Maciej M. , Bendok, Bernard R. , Swanson, Kristin R. , Swanson, Kristin R , Massey, Susan Christine , Leon, Gustavo De, Rubin, Joshua B

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi179-vi179

10.1093/neuonc/noy148.743 Get It

Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales
Tay, Jason , Vij, Ravi , Norkin, Maxim , Kindwall‐Keller, Tamila L. , Roberts, Jenna , White, Darrell , Wood, Robert , Blanthorn-Hazell, Sophee , Rossi, Adriana , Dhanasiri, Sujith, Zafar, Faiza , Newhouse, Kim, McCurdy, Arleigh , Buadi, Francis K. , Rossi, Adriana , McCurdy, Arleigh

Mayo Clinic

Leukemia & Lymphoma | October 31, 2018 | Volume: 60 | Issue: 5 | Pages: 1275-1282

10.1080/10428194.2018.1523399 | PMID 30380358 Get It

Association of Clinical Specialty With Symptoms of Burnout and Career Choice Regret Among US Resident Physicians
Burke, Sara E. , Wittlin, Natalie M. , Yeazel, Mark W. , Dovidio, John F. , Cunningham, Brooke A. , White, Richard O. , Satele, Daniel , Shanafelt, Tait D. , Ryn, Michelle van , Dyrbye, Liselotte N. , Phelan, Sean M. , Satele, Daniel V, Shanafelt, Tait D , van Ryn, Michelle , Hardeman, Rachel R. , Herrin, Jeph

Mayo Clinic

JAMA | October 26, 2018 | Volume: 320 | Issue: 11 | Pages: 1114

10.1001/jama.2018.12615 | PMID 30422299 Get It

Factors influencing medical student self‐competence to provide weight management services
Doshi, Ruchi S. , Gudzune, Kimberly A. , Burke, Sara E. , White, Richard O. , Perry, Sylvia , Yeazel, Mark W. , Ryn, Michelle van , Doshi, R S , Gudzune, K A , Perry, Sylvia P , van Ryn, Michelle , Dyrbye, Liselotte N. , Dovidio, John F. , Phelan, Sean M.

Mayo Clinic

Clinical Obesity | October 25, 2018 | Volume: 9 | Issue: 1 | Pages: No page available

10.1111/cob.12288 | PMID 30358159 Get It

SummaryThis study aimed to identify factors associated with high obesity care self‐competence among US medical students. The authors performed a cross‐sectional analysis of 2014 survey data on fourth year medical students collected online as part of the Medical Student Cognitive Habits and Growth Evaluation Study (CHANGES). Independent variables included quality and quantity of interaction with patients and peers with obesity; hours of communication and partnership skills training; negative remarks against patients with obesity by supervising physicians, and witnessed discrimination against patients with obesity. The dependent variable was self‐competence in providing obesity care. Of 5823 students invited to participate, 3689 (63%) responded and were included in our analyses. Most students were white (65%), half were women and 42% had high self‐competence in caring for patients with obesity. Factors associated with high self‐competence included increased interaction with peers with obesity (39% vs. 49%, P < 0.001) and increased partnership skills training (32% vs. 61%, P < 0.001). Increased partnership skills training and quantity of interactions with peers with obesity were associated with high student self‐competence in providing obesity‐related care to patients. Medical schools might consider increasing partnership skills training to improve students’ preparedness and skill in performing obesity‐related care.